Market capitalization | $9.98b |
Enterprise Value | $10.42b |
P/E (TTM) P/E ratio | 111.44 |
EV/FCF (TTM) EV/FCF | 22.48 |
EV/Sales (TTM) EV/Sales | 5.30 |
P/S ratio (TTM) P/S ratio | 5.08 |
P/B ratio (TTM) P/B ratio | 2.83 |
Revenue growth (TTM) Revenue growth | 0.62% |
Revenue (TTM) Revenue | $1.97b |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
23 Analysts have issued a QIAGEN NV forecast:
23 Analysts have issued a QIAGEN NV forecast:
Sep '24 |
+/-
%
|
||
Revenue | 1,966 1,966 |
1%
1%
|
|
Gross Profit | 1,231 1,231 |
1%
1%
|
|
EBITDA | 681 681 |
6%
6%
|
EBIT (Operating Income) EBIT | 472 472 |
8%
8%
|
Net Profit | 93 93 |
72%
72%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
Head office | Netherlands |
CEO | Thierry Bernard |
Employees | 5,967 |
Founded | 1996 |
Website | www.qiagen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.